ValuEngine Downgrades Lannett (LCI) to Sell

Share on StockTwits

Lannett (NYSE:LCI) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports.

LCI has been the topic of several other research reports. Zacks Investment Research upgraded shares of Lannett from a “sell” rating to a “hold” rating in a research note on Wednesday, January 16th. SunTrust Banks initiated coverage on shares of Lannett in a research note on Tuesday, March 19th. They issued a “hold” rating and a $9.00 target price on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a strong buy rating to the company’s stock. Lannett presently has an average rating of “Hold” and an average price target of $19.45.

NYSE:LCI opened at $7.03 on Tuesday. Lannett has a one year low of $3.33 and a one year high of $17.58. The company has a debt-to-equity ratio of 2.29, a quick ratio of 1.88 and a current ratio of 2.44. The stock has a market cap of $292.32 million, a P/E ratio of 2.27 and a beta of 2.45.

Lannett (NYSE:LCI) last issued its earnings results on Wednesday, February 6th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.18. The firm had revenue of $193.70 million for the quarter, compared to the consensus estimate of $162.51 million. Lannett had a negative net margin of 39.44% and a positive return on equity of 22.88%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.06 earnings per share. Research analysts anticipate that Lannett will post 2.14 EPS for the current fiscal year.

In related news, CEO Timothy C. Crew acquired 4,000 shares of the stock in a transaction that occurred on Monday, February 11th. The shares were bought at an average price of $8.48 per share, for a total transaction of $33,920.00. Following the completion of the transaction, the chief executive officer now directly owns 45,988 shares in the company, valued at $389,978.24. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Patrick G. Lepore acquired 25,000 shares of the stock in a transaction that occurred on Tuesday, February 12th. The shares were bought at an average price of $8.93 per share, for a total transaction of $223,250.00. The disclosure for this purchase can be found here. Corporate insiders own 12.57% of the company’s stock.

A number of institutional investors have recently modified their holdings of LCI. BlackRock Inc. lifted its position in Lannett by 70.9% during the fourth quarter. BlackRock Inc. now owns 4,765,936 shares of the company’s stock valued at $23,639,000 after purchasing an additional 1,976,599 shares during the period. JPMorgan Chase & Co. lifted its position in Lannett by 582.7% during the third quarter. JPMorgan Chase & Co. now owns 684,622 shares of the company’s stock valued at $3,251,000 after purchasing an additional 584,343 shares during the period. Canada Pension Plan Investment Board lifted its position in Lannett by 105.1% during the fourth quarter. Canada Pension Plan Investment Board now owns 1,102,998 shares of the company’s stock valued at $5,470,000 after purchasing an additional 565,198 shares during the period. Alambic Investment Management L.P. bought a new position in Lannett during the fourth quarter valued at approximately $2,082,000. Finally, Two Sigma Investments LP bought a new position in Lannett during the fourth quarter valued at approximately $1,366,000. Institutional investors own 82.05% of the company’s stock.

Lannett Company Profile

Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.

See Also: Understanding Compound Annual Growth Rate (CAGR)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Lannett (NYSE:LCI)

Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Maker  Market Cap Reaches $680.31 Million
Maker Market Cap Reaches $680.31 Million
Zacks: Liberty Braves Group Series A  Given $43.00 Average Price Target by Brokerages
Zacks: Liberty Braves Group Series A Given $43.00 Average Price Target by Brokerages
Peony  Reaches Market Cap of $4,449.00
Peony Reaches Market Cap of $4,449.00
Zacks: Brokerages Expect Schneider National Inc  Will Announce Quarterly Sales of $1.30 Billion
Zacks: Brokerages Expect Schneider National Inc Will Announce Quarterly Sales of $1.30 Billion
imbrex Hits 1-Day Volume of $204.00
imbrex Hits 1-Day Volume of $204.00
Electroneum  Trading 10.8% Higher  Over Last Week
Electroneum Trading 10.8% Higher Over Last Week


© 2006-2019 Ticker Report